The study, the first head-to-head comparison of the two, was funded by Lilly. Novo Nordisk’s share price is down 54% from its peak in June 2024. Its U.S.-listed shares fell another 3% in morning ...

From the end of January 2017 to May 16, Novo Nordisk achieved a total return of approximately 304%. This significantly outpaced the approximately 199% return of the S&P 500 Index over that period.

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say the company's cautious culture is to blame.

Novo Nordisk said on Thursday it plans to start late-stage trials of its experimental weight-loss drug, amycretin, in injection and oral forms during the first quarter of 2026 for adults who are ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...